Status:
ENROLLING_BY_INVITATION
Evaluation of PatientToc in Community Pharmacies
Lead Sponsor:
Purdue University
Collaborating Sponsors:
University of Wisconsin, Madison
University of Minnesota
Conditions:
Medication Adherence
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate the initial "spread and scale" of PatientToc™, a patient-reported outcomes (PROs) collection software, to community pharmacies for the collection and use of PR...
Detailed Description
Medication non-adherence is a problem of critical importance, affecting approximately 50% of all persons taking at least one regularly scheduled prescription medication and costing the United States m...
Eligibility Criteria
Inclusion
- Pharmacist/pharmacy staff eligibility criteria:
- Aged 18 years or older
- Employee (paid) or PharmD rotation student trainee/volunteer at the pharmacy during the time of PatientToc™ implementation
- Pharmacy patient eligibility criteria:
- The specific pharmacy workflow for introducing patients to PatientToc™ may vary by participating pharmacy. For example, all pharmacy patients might have the opportunity to complete PROs in the tablet/mobile application (if desired by the pharmacy) with only a subset included in our evaluation. This variation does not change our study/evaluation procedures and is allowed to facilitate successful PatientToc™ implementation in patient care.
- For the purposes of this evaluation, individual-level data will be sought from patients who are:
- ≥ 50 years of age
- Have one or more specific chronic conditions (i.e., hypertension, Type 2 diabetes, and dyslipidemia; per self-report, ICD code if available, and/or inferred by medications filled) requiring routine (regularly scheduled, not "as needed" dosing)
- Medications are oral (solid dosage form)
- Prescription medication filled at least once previously by the study pharmacy as 30-day supplies. In situations where patients with 30-day supplies also fill some medications as 90-day (or other quantity) supplies, they will be enrolled if their first medication chosen for PROs completion was a 30-day supply.
- Baseline non-adherence as determined by responses to the BMQ PRO for one or more targeted medications, specifically, the first medication chosen for PROs completion by the patient for their primary condition of interest (hypertension, Type 2 diabetes, and dyslipidemia) when they have more than one of these conditions and take more than one targeted medication.
- Able to provide consent and read and/or comprehend English or another language for which the intervention and study materials (e.g., consent documents) is available OR has a legal representative (self-reported) with authority to act on their behalf to complete PROs/interview/other data collection and consent documents.
Exclusion
Key Trial Info
Start Date :
July 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 28 2024
Estimated Enrollment :
1175 Patients enrolled
Trial Details
Trial ID
NCT05235620
Start Date
July 1 2023
End Date
March 28 2024
Last Update
April 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Purdue University
West Lafayette, Indiana, United States, 46202